Mark de Rosch

Plus aucun poste en cours Fortune : 34 344 $ au 31/03/2024

Profil

Mark de Rosch worked as a Senior Director-Global Regulatory Strategy at Vertex Pharmaceuticals, Inc. from 2003 to 2012, as a Director-Regulatory Affairs at Berlex Laboratories, Inc. from 2001 to 2003, as a Vice President-Regulatory Affairs at Inspiration Biopharmaceuticals, Inc. from 2012 to 2013, as a Senior VP-Regulatory Affairs & Quality Assurance at Akebia Therapeutics, Inc. from 2014 to 2018, as a Chief Regulatory Officer at Epizyme, Inc. from 2019 to 2021, and as a Senior VP-Regulatory Affairs & Quality Assurance at Nightstar Therapeutics Ltd.
in 2018-2019.
He also worked as a Research Chemist at Mallinckrodt Medical, Inc. from 1992 to 1994 and at Diatide, Inc. from 2000 to 2001.
Dr. de Rosch holds a graduate and doctorate degree from the University of California San Diego and an undergraduate degree from the University of Wisconsin Parkside.
He also worked as a VP-Regulatory Drugs & US Operations at Voisin Consulting, Inc.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
AURA BIOSCIENCES INC 0,01%	31/03/2023	4 375 ( 0,01% )	34 344 $	31/03/2024

Anciens postes connus de Mark de Rosch

Sociétés	Poste	Fin
AURA BIOSCIENCES, INC.	Chief Operating Officer	30/05/2023
EPIZYME, INC.	General Counsel	01/03/2021
NIGHTSTAR THERAPEUTICS PLC	General Counsel	01/09/2019
AKEBIA THERAPEUTICS, INC.	General Counsel	01/02/2018
Inspiration Biopharmaceuticals, Inc.	General Counsel	01/05/2013

Formation de Mark de Rosch

University of California San Diego	Doctorate Degree
University of Wisconsin Parkside	Undergraduate Degree